Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients

NCT00098241 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to evaluate the safety and tolerability of RAD001 (Certican) administered to pediatric renal transplant recipients, and to provide additional safety data.

Conditions Studied

Interventions

  • DRUG Certican

Study Locations (2)

Ohio

  • Columbus Children's Hospital — Columbus

Other

  • Dienst Pediatrie UZ Gasthuisberg, Herestraat 49 — Leuven

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2000-06
Est. Completion 2007-03
Phase Phase 3

Sponsor

Novartis Pharmaceuticals

792 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00098241

The ClinicalTrials.gov registry entry for NCT00098241 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 792 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Kidney Transplantation appearing as the primary indexed condition, and to 1 intervention — of which Certican is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00098241 reports 2 study locations spanning 2 distinct geographic areas — top geographies include Ohio, Other. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00098241 about?

NCT00098241 is a clinical study titled "Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients". The purpose of this study is to evaluate the safety and tolerability of RAD001 (Certican) administered to pediatric renal transplant recipients, and to provide additional safety data.

What is the current status of trial NCT00098241?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 45 participants. The study started on 2000-06. Estimated completion is 2007-03.

What conditions does trial NCT00098241 study?

This clinical trial studies the following conditions: Kidney Transplantation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00098241?

The interventions under investigation include: Certican (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00098241?

This trial is sponsored by Novartis Pharmaceuticals, which has 792 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00098241 being conducted?

This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial